Search results for " angiotensin"

showing 10 items of 72 documents

Incidence, risk factors, and thrombotic load of pulmonary embolism in patients hospitalized for COVID-19 infection

2021

Summary Objective To determine the incidence, characteristics, and risk factors of pulmonary embolism (PE) among patients hospitalized for COVID-19. Patients and Methods We performed a prospective observational study of a randomly selected cohort of consecutive patients hospitalized for COVID-19 infection between March 8, 2020 through April 25, 2020. All eligible patients underwent a computed tomography pulmonary angiography independently of their PE clinical suspicion and were pre-screened for a baseline elevated D-dimer level. Results 119 patients were randomly selected from the 372 admitted to one tertiary hospital in Valencia (Spain) for COVID-19 infection during the period of study. Se…

Male0301 basic medicineCTPA Computed tomography pulmonary angiographyAUC-ROC Area under curve ROCPCR polymerase chain reaction0302 clinical medicineRisk FactorsspO2 Oxygen saturationIL6 Interleukin-6Pulmonary angiographySD Standard deviationMedicineProspective Studies030212 general & internal medicineProspective cohort studyComputed tomographyFramingham Risk ScoreIncidenceIncidence (epidemiology)RV Right ventricleHazard ratioVenous ThromboembolismMiddle AgedAo Aortic arteryPulmonary embolismCXR chest X-rayHospitalizationInfectious DiseasesCohortCRP C-reactive proteinFemalePA Pulmonary artery trunkMicrobiology (medical)medicine.medical_specialty030106 microbiologysPESI Simplified Pulmonary Embolism Severity IndexBMI Body mass indexPE Pulmonary embolismLV Left ventricleVTE Venous thromboembolismFibrin Fibrinogen Degradation Products03 medical and health sciencesInternal medicineHumansICU Intensive care unitsACE2 Angiotensin converting enzyme-2AgedInflammationLDH Lactate dehydrogenaseSARS-CoV-2 Severe acute respiratory syndrome coronavirus 2CI Confidence intervalbusiness.industryPulmonary embolismCOVID-19AnticoagulantsThrombosisRR Respiratory ratemedicine.diseaseConfidence intervalCHOD CRP concentration + Heart rate + Oxygen saturation + D-dimer levelsSpainHR Hazard RatioCommentarybusinessJournal of Infection
researchProduct

PD123319, angiotensin II type II receptor antagonist, inhibits oxidative stress and inflammation in 2, 4-dinitrobenzene sulfonic acid-induced colitis…

2019

Angiotensin II, the main effector of renin angiotensin system, plays an important role in the inflammatory process and most of its effects are mediated through the AT1 receptor activation. However, the knowledge about the AT2 receptor involvement in this process is still evolving. We previously found that in an experimental model of colitis, AT2 receptor activation can contribute to the impairment of the muscle contractility in vitro in the course of inflammation. Here, we investigated the potential alleviating effects of the in vivo treatment of PD123319 (1-[[4-(Dimethylamino)-3-methylphenyl]methyl]-5-(diphenylacetyl)-4,5,6,7- tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid ditriflu…

Male0301 basic medicineColonPyridinesmedicine.drug_classImmunologyAngiotensin II Type 2 Receptor BlockersPharmacologyAT2 receptorReceptor Angiotensin Type 2Inflammatory bowel diseaseInflammatory bowel diseaseProinflammatory cytokineContractility03 medical and health sciencesAngiotensin0302 clinical medicinemedicineAnimalsPharmacology (medical)Rats WistarColitisReceptorPharmacologyInflammationAngiotensin II receptor type 1ChemistryAngiotensin IIImidazolesColitismedicine.diseaseReceptor antagonistAngiotensin IIRatsDinitrobenzenesOxidative Stress030104 developmental biology030217 neurology & neurosurgery
researchProduct

Role of angiotensin II in arterial pressure and renal hemodynamics in rats with altered renal development: age- and sex-dependent differences

2012

Numerous studies have demonstrated that angiotensin II (ANG II) is involved in hypertension and renal changes occurring as a consequence of an adverse event during renal development. However, it was unknown whether this involvement is sex and age dependent. This study examines whether the increments in arterial pressure (AP) and in the renal sensitivity to ANG II are sex and age dependent in rats with altered renal development. It also evaluates whether the ANG II effects are accompanied by increments in AT1 receptors and oxidative stress. Experiments were performed in 3- to 4- and 10- to 11-mo-old rats treated with vehicle or an AT1 receptor antagonist (ARAnp) during the nephrogenic perio…

MaleAgingmedicine.medical_specialtyPhysiologyTetrazolesRenal functionKidneyAge and sexmedicine.disease_causeReceptor Angiotensin Type 1Rats Sprague-DawleyInternal medicinemedicineAnimalsArterial PressureRenal hemodynamicsFetal programmingAdverse effectSex CharacteristicsChemistryAngiotensin IIBiphenyl CompoundsAngiotensin IIMesenteric ArteriesRatsOxidative StressEndocrinologyBlood pressureBenzimidazolesFemaleAngiotensin II Type 1 Receptor BlockersOxidative stressAmerican Journal of Physiology-Renal Physiology
researchProduct

Interaction between Angiotensin Type 1, Type 2, and Mas Receptors to Regulate Adult Neurogenesis in the Brain Ventricular–Subventricular Zone

2019

The renin&ndash

MaleAgingproliferationNeurogenesisProliferationSubventricular zoneventricular–subventricular zoneBiologyModels BiologicalReceptor Angiotensin Type 2ArticleReceptor Angiotensin Type 1MiceNeuroblastNeural Stem CellsLateral VentriclesmedicineneurospheresAT1 receptorsAnimalsReceptorNeural stem cellsMice KnockoutAngiotensin II receptor type 1Cell growthAngiotensin IINeurogenesisagingAge FactorsGeneral MedicineImmunohistochemistryNeural stem cellOlfactory bulbCell biologyRatsVentricular–subventricular zonemedicine.anatomical_structurenervous systemAT2 receptorscardiovascular systemNeurosphereshormones hormone substitutes and hormone antagonistscirculatory and respiratory physiologyProtein BindingCells
researchProduct

SARS CoV2 infection _The longevity study perspectives

2021

Graphical abstract

MaleAgingssRNA single-stranded RNARFLP restriction fragment length polymorphismHSPs heat shock proteinsReviewPTMs post-translational modificationsSevere Acute Respiratory SyndromeBiochemistryHIV-1 human immunodeficiency virus-1TNF-α tumor necrosis factor-αEC endothelial cells0302 clinical medicineFluAV influenza A virusI insertionMedicineIFN-γ interferon-γDIC disseminated intravascular coagulationPCR Polymerase Chain Reactionmedia_commonAged 80 and overLongevityRBD receptor-binding domainNeurologyLongevity modelMI myocardial infarctionNK natural killerhPIV2 human parainfluenza virus type 2media_common.quotation_subjectResearching genetic basis of resistance and potential pharmacological targetsLongevityDBP diastolic blood pressureNF-Kb nuclear transcription factor kBRANTES regulated upon activation normal T cell expressed and secretedMphi human macrophages03 medical and health sciencesCox 2 cyclooxygenase 2ORF open reading framePT prothrombin timeSettore MED/05 - Patologia ClinicaHumansMolecular BiologyInflammatory genesARDS acute respiratory distress syndromeNO nitric oxideD deletionCpGIs CpG islandsT2DM type 2 diabetes mellitusmedicine.diseaseFDP fibrin degradation products030104 developmental biologySARS CoV2 severe acute respiratory syndrome Coronavirus 2 virusImmunologyBMI body max indexItalian nonagenarians/centenariansRSV respiratory syncytial virusComplication030217 neurology & neurosurgeryMAPK mitogen-activated protein kinaseIP-10 IFN-γ -Inducible Protein 1040301 basic medicineAT1R activity of angiotensin 1 receptorsDCs dentritic cellsSSCP single strand conformation polymorphismACE/DD polymorphism of the angiotensin converting enzymeFGF21 fibroblast growth factor 21TLR4 toll-like receptor 4NAD nicotinamide adenine dinucleotideACE angiotensin-I converting enzymeAT2R activity of angiotensin 2 receptorsCOVID-19 Coronavirus disease 2019Respiratory distressACE2 angiotensin converting enzyme 2MKP-1 mitogen-activated protein kinase phosphatase-1 ()PD protease domainSNP single nucleotide polymorphismEH essential hypertensionTNFR tumor necrosis factor receptorINR international normalized ratio of the prothrombin timePAI-1 plasminogen activator inhibitor-1Ang angiotensinLPS lipopolysaccharideMCP1 monocyte chemoattractant protein-1medicine.symptomaPTT partial thromboplastin timeBiotechnologyDUSP1 dual specificity phosphatase 1Coronavirus disease 2019 (COVID-19)PC prostate cancerRAS renin-angiotensin aldosterone systemCCR5Δ32 genetic variant of chemokine receptorCOVID-19 Researching genetic basis of resistance and potential pharmacological targets Italian nonagenarians/centenarians Longevity modelAsymptomaticSARS-1 severe acute respiratory syndrome virus 1SIRT-1 Sirtuin 1Th1 t-helper lymphocyte type 1Immune systemROS reactive oxygen speciesTGF-β transforming growth factor betaET-1 endothelin-1ComputingMethodologies_COMPUTERGRAPHICSADAM-17 metallopeptidase domain 17business.industrySARS-CoV-2SBP systolic blood pressureCOVID-19HDACs histone deacetylasesComorbidityImmune Systembusiness5-LO lipoxygenase 5Ageing Research Reviews
researchProduct

Stimulation of the AT2 receptor reduced atherogenesis in ApoE−/−/AT1A−/− double knock out mice

2012

AT1 receptor blockers (ARB) and in part ACE inhibitors (ACI) potentially exert beneficial effects on atherogenesis independent of AT1 receptor inhibition. These pleiotropic effects might be related to angiotensin II mediated activation of the AT2 receptor. To analyze this hypothesis we investigated the development of atherosclerosis and the role of ACIs and ARBs in apolipoprotein E-deficient (ApoE(-/-)) mice and in ApoE/AT1A receptor double knockout mice (ApoE(-/-)/AT1A(-/-)). ApoE(-/-) mice and ApoE(-/-)/AT1A(-/-) mice were fed cholesterol-rich diet for 7 weeks. Vascular oxidative stress, endothelial dysfunction, and atherosclerotic lesion formation were evident in ApoE(-/-) mice, but were…

MaleApolipoprotein ERamiprilmedicine.medical_specialtyApolipoprotein BReceptor expressionGene ExpressionAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin II Type 2 Receptor BlockersIn Vitro TechniquesReceptor Angiotensin Type 2Receptor Angiotensin Type 1MiceApolipoproteins EInternal medicinemedicineAnimalsReceptorMolecular BiologyMice KnockoutAngiotensin II receptor type 1biologyChemistryAtherosclerosisLipidsAngiotensin IIMice Inbred C57BLOxidative StressEndocrinologybiology.proteinBlood Vesselslipids (amino acids peptides and proteins)Inflammation MediatorsTelmisartanCardiology and Cardiovascular Medicinehormones hormone substitutes and hormone antagonistsmedicine.drugJournal of Molecular and Cellular Cardiology
researchProduct

Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A…

2016

Summary Objective In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as dia…

MaleCaptoprilDiabetic CardiomyopathiesMyocardial InfarctionInfarctionAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineDiabetes mellitusRamiprilRetrospective StudieCardiovascular DiseaseMedicinePharmacology (medical)030212 general & internal medicineMyocardial infarctionDiabetic CardiomyopathieRandomized Controlled Trials as TopicAspirinLeft ventricular dysfunctionGeneral MedicineAcetyl salicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Diabetes mellitus; Left ventricular dysfunction; Ramipril; Zofenopril; Cardiology and Cardiovascular Medicine; Pharmacology (medical); PharmacologyMiddle AgedZofenoprilAcetyl salicylic acidCardiovascular DiseasesCardiologyPlatelet aggregation inhibitorDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugHumanRamiprilmedicine.medical_specialtyDiabetes mellituSystoleAcute myocardial infarctionZofenopril03 medical and health sciencesDiabetes mellitusInternal medicineHumansAgedRetrospective StudiesPharmacologyAspirinbusiness.industryPlatelet Aggregation InhibitorAngiotensin-Converting Enzyme Inhibitormedicine.diseasechemistryAngiotensin-converting enzyme inhibitorbusinessMacePlatelet Aggregation Inhibitors
researchProduct

Age and Multimorbidity Predict Death Among COVID-19 Patients: Results of the SARS-RAS Study of the Italian Society of Hypertension

2020

Several factors have been proposed to explain the high death rate of the coronavirus disease 2019 (COVID-19) outbreak, including hypertension and hypertension-related treatment with Renin Angiotensin System inhibitors. Also, age and multimorbidity might be confounders. No sufficient data are available to demonstrate their independent role. We designed a cross-sectional, observational, multicenter, nationwide survey in Italy to verify whether renin-angiotensin system inhibitors are related to COVID-19 severe outcomes. We analyzed information from Italian patients diagnosed with COVID-19, admitted in 26 hospitals. One thousand five hundred ninety-one charts (male, 64.1%; 66±0.4 years) were r…

MaleCross-sectional studyAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyRenin-Angiotensin System0302 clinical medicine80 and overMedicineodds ratioodds ratio.030212 general & internal medicineViralYoung adultSocieties MedicalAged 80 and overCOVID-19; hypertension; Italy; multimorbidity; odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalMortality rateAge FactorsMiddle AgedPrognosisSurvival RateItalyCOVID-19; hypertension; Italy; multimorbidity; odds ratioFemaleCoronavirus InfectionsAdultmedicine.medical_specialtyhypertensionAdolescentmultimorbidityPneumonia ViralCOVID-19; Italy; hypertension; multimorbidity; odds ratio03 medical and health sciencesAngiotensin Receptor AntagonistsYoung AdultBetacoronavirusAge DistributionInternal medicineDiabetes mellitusMedicalInternal MedicineHumansSurvival ratePandemicsAgedbusiness.industrySARS-CoV-2COVID-19Odds ratioPneumoniamedicine.diseaseCross-Sectional StudiesHeart failureCOVID-19; Hypertension; Italy; Multimorbidity; Odds ratio; Adolescent; Adult; Age Distribution; Age Factors; Aged; Aged 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19; Coronavirus Infections; Cross-Sectional Studies; Female; Humans; Hypertension; Italy; Male; Middle Aged; Multimorbidity; Pandemics; Pneumonia Viral; Prognosis; Renin-Angiotensin System; SARS-CoV-2; Survival Rate; Young Adult; Betacoronavirus; Societies MedicalbusinessSocietiesKidney disease
researchProduct

Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry)

2017

IF 3.398; International audience; The prognosis of patients with acute myocardial infarction (AMI) has notably improved in the past 20 years. Using the French Registry of ST-Elevation and Non-ST-elevation Myocardial Infarction (FAST-MI) 2010 registry, we investigated whether previous manifestations of atherosclerotic disease (i.e., previous MI, or a history of any form of atherosclerotic disease) are at truly increased risk compared with those in whom AMI is the first manifestation of the disease. FAST-MI 2010 is a nationwide French registry including 3,079 patients with AMI, among whom 1,062 patients had a history of cardiovascular atherosclerotic disease and 498 patients had a history of …

MaleMESH : Atherosclerosismedicine.medical_treatmentMESH : MortalityMyocardial InfarctionMESH : AgedMESH : Prospective StudiesAngiotensin-Converting Enzyme InhibitorsCoronary Artery DiseaseDiseaseMESH : Cerebrovascular Disorders0302 clinical medicineMedicineLongitudinal StudiesProspective StudiesMESH: Coronary Artery DiseaseMyocardial infarctionCoronary Artery BypassMESH: Treatment OutcomeCause of deathAged 80 and overeducation.field_of_studyMESH: Middle AgedHazard ratioMESH : Platelet Aggregation InhibitorsPrognosisMESH: Case-Control Studies3. Good healthMESH: Myocardial InfarctionMESH: Angiotensin Receptor AntagonistsMESH : Angiotensin-Converting Enzyme InhibitorsCardiology and Cardiovascular MedicineMESH: Percutaneous Coronary InterventionMESH : Case-Control Studiesmedicine.medical_specialtyMESH : Angiotensin Receptor AntagonistsMESH: Prognosis03 medical and health sciencesPercutaneous Coronary Intervention[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemHumansMESH : Middle AgedMESH : Coronary Artery DiseaseMESH : Aged 80 and overMESH: Hydroxymethylglutaryl-CoA Reductase InhibitorseducationMESH: Age DistributionAgedMESH: HumansMESH: MortalityProportional hazards modelMESH: Coronary Artery BypassMESH : HumansCase-control studyMESH : Proportional Hazards Modelsmedicine.diseaseMESH : Coronary Artery BypassCase-Control StudiesMESH: FemaleMESH: RegistriesMESH : Age Distribution030204 cardiovascular system & hematologyMESH: AtherosclerosisMESH: Proportional Hazards ModelsMESH: Cause of DeathMESH: Aged 80 and overMESH : Percutaneous Coronary InterventionRisk FactorsMESH: Risk FactorsCause of DeathMESH : FemaleRegistries030212 general & internal medicineMESH: Longitudinal StudiesMESH : Longitudinal StudiesMESH: AgedMESH : PrognosisMESH: Angiotensin-Converting Enzyme InhibitorsMESH: Adrenergic beta-AntagonistsMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemMESH : Risk FactorsTreatment OutcomeMESH: Platelet Aggregation InhibitorsCardiologyFemaleMESH: Cerebrovascular DisordersFranceMESH : MaleAdrenergic beta-AntagonistsMESH : Adrenergic beta-AntagonistsPopulationMESH : Treatment OutcomeMESH: Multivariate AnalysisAngiotensin Receptor AntagonistsAge DistributionInternal medicineMortalityMESH : FranceProportional Hazards ModelsMESH : Cause of Deathbusiness.industryMESH : Hydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Multivariate AnalysisPercutaneous coronary interventionAtherosclerosisMESH: MaleMESH: Prospective StudiesMESH: FranceCerebrovascular DisordersMultivariate AnalysisHydroxymethylglutaryl-CoA Reductase InhibitorsMESH : Myocardial InfarctionbusinessPlatelet Aggregation InhibitorsMESH : RegistriesThe American Journal of Cardiology
researchProduct

Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Surviv…

2016

Introduction: This was a propensity score analysis of the prospective, randomized, double-blind Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study in which one-year treatment with zofenopril 60 mg plus acetylsalicylic acid (ASA) 100 mg gave superior results compared to ramipril 10 mg plus ASA in terms of death or hospitalization for cardiovascular causes in patients with acute myocardial infarction (AMI) complicated by left ventricular dysfunction (LVD). Materials and methods: A total of 716 patients of the intention-to-treat population were divided into homogeneous propensity quintiles (Q) using a logistic regression model (QI: best risk profile; QV: worst risk profile)…

MaleMedicine (General)Time FactorsCaptoprilIntention to Treat AnalysiLeftMyocardial Infarction030204 cardiovascular system & hematologychemistry.chemical_compoundVentricular Dysfunction Left0302 clinical medicineEndocrinologyRamiprilPropensity analysisAcetylsalicylic acid; Acute myocardial infarction; Angiotensin-converting enzyme inhibitors; Left ventricular dysfunction; Propensity analysis; Captopril; Demography; Drug Therapy Combination; Endpoint Determination; Female; Hospitalization; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Ramipril; Survival Analysis; Time Factors; Ventricular Dysfunction Left; Propensity Score; Internal Medicine; EndocrinologyVentricular DysfunctionMedicine030212 general & internal medicineMyocardial infarctioneducation.field_of_studyLeft ventricular dysfunctionElectrocardiography in myocardial infarctionMiddle AgedZofenoprilIntention to Treat AnalysisHospitalizationCombinationCardiologyOriginal ArticleDrug Therapy CombinationFemaleSurvival AnalysiPropensity analysimedicine.drugHumanRamiprilmedicine.medical_specialtyTime FactorEndpoint DeterminationPopulationAcute myocardial infarction03 medical and health sciencesR5-920Drug TherapyInternal medicineAngiotensin-converting enzyme inhibitorsAcetylsalicylic acidInternal MedicineHumanseducationPropensity ScoreDemographybusiness.industryOdds ratiomedicine.diseaseSurvival AnalysisConfidence intervalchemistryAngiotensin-converting enzyme inhibitorPropensity score matchingbusiness
researchProduct